Last reviewed · How we verify
anti-EGFR monoclonal antibody
anti-EGFR monoclonal antibody is a Small molecule drug developed by Dragonboat Biopharmaceutical Company Limited. It is currently in Phase 2 development. Also known as: CDP1, SCT200, cetuximab β.
At a glance
| Generic name | anti-EGFR monoclonal antibody |
|---|---|
| Also known as | CDP1, SCT200, cetuximab β |
| Sponsor | Dragonboat Biopharmaceutical Company Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery (PHASE1, PHASE2)
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (PHASE3)
- Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation (PHASE2)
- Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor (PHASE1)
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer (PHASE3)
- Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment (PHASE3)
- Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer (PHASE1)
- Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-EGFR monoclonal antibody CI brief — competitive landscape report
- anti-EGFR monoclonal antibody updates RSS · CI watch RSS
- Dragonboat Biopharmaceutical Company Limited portfolio CI
Frequently asked questions about anti-EGFR monoclonal antibody
What is anti-EGFR monoclonal antibody?
anti-EGFR monoclonal antibody is a Small molecule drug developed by Dragonboat Biopharmaceutical Company Limited.
Who makes anti-EGFR monoclonal antibody?
anti-EGFR monoclonal antibody is developed by Dragonboat Biopharmaceutical Company Limited (see full Dragonboat Biopharmaceutical Company Limited pipeline at /company/dragonboat-biopharmaceutical-company-limited).
Is anti-EGFR monoclonal antibody also known as anything else?
anti-EGFR monoclonal antibody is also known as CDP1, SCT200, cetuximab β.
What development phase is anti-EGFR monoclonal antibody in?
anti-EGFR monoclonal antibody is in Phase 2.
Related
- Manufacturer: Dragonboat Biopharmaceutical Company Limited — full pipeline
- Also known as: CDP1, SCT200, cetuximab β
- Compare: anti-EGFR monoclonal antibody vs similar drugs
- Pricing: anti-EGFR monoclonal antibody cost, discount & access